FDA urge block on Masters pharmaceutical Opioid Sales
DEA Urges Court to Block Opioid Supplier’s Sales
July 20, 2017
The U.S. Drug Enforcement Administration has urged the D.C. Circuit Court to block Masters Pharmaceutical, a maker of opioids and other prescription painkillers, from selling controlled substances.
In 2013, Masters allegedly failed to report to the DEA a number of “suspicious” orders from Florida for its opioid-based oxycodone medications, leading the DEA to revoke Masters’ registration in 2015. The company petitioned that revocation, and has been operating under the terms of a court-ordered stay. Now, the DEA has urged that the stay be rescinded, thus effectively prohibiting Masters from selling opioid medications.
Florida’s governor declared that the state was in a “state of emergency” with regard to the opioid problem. Opioid abuse has killed some 30,000 Americans over the last several years.
Masters is one of several pharmaceutical manufacturers that have come under fire for their roles in supplying the drugs that are being fatally abused.
The results of the DEA’s request are pending.
If your life, or that of a loved one, has been wrecked by opioid abuse, you may have legal recourse. Contact the expert attorneys at TheLawFirm.com to learn how we can help you.
TheLawFirm.com’s award winning lawyers have been featured in over 50 radio and television interviews including:
Real lawyers, real results!
no recovery, no fee!